Fingerprint
Dive into the research topics of '6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically